Crown Laboratories will be working with Suneva Medical to co-promote ReFissa (tretinoin cream, USP (Emollient) 0.05%), FDA approved and marketed as an adjunctive agent for use in the mitigation of fine wrinkles, mottled hyperpigmentation and tactile roughness of facial skin.
“Our strategic relationship with Crown Laboratories—an industry leader with expertise that spans the full spectrum of the skin care channel—ensures more health care practitioners can access ReFissa, a unique and valuable product for the dermatology community treating antiaging concerns,” said Nicholas L. Teti, Jr., chairman and CEO of Suneva Medical. “The Crown Laboratories partnership is a welcome addition that enhances our footprint across the aesthetics industry.”
